pone.0177146.g003.tif (4.46 MB)
In vivo therapeutic activity of systemic tTF-NGR against CD13+ A549 tumor xenografts.
figure
posted on 2017-06-12, 17:31 authored by Lars Henning Schmidt, Caroline Brand, Janine Stucke-Ring, Christoph Schliemann, Torsten Kessler, Saliha Harrach, Michael Mohr, Dennis Görlich, Alessandro Marra, Ludger Hillejan, Carsten Müller-Tidow, Georg Lenz, Eva Wardelmann, Rainer Wiewrodt, Wolfgang E. Berdel, Christian Schwöppe, Wolfgang HartmannTo investigate CD13 expression flow cytometry was performed with a monoclonal PE-labeled anti-CD13 antibody. CD13 expression was found in 47% of the A549 lung cancer cells (green, control; purple, CD13) (Fig. 3A). Following treatment with tTF-NGR (1 mg tTF-NGR/kg x4 (arrows); i.v.; n = 4 CD-1 nude mice) tumor growth of subcutaneous A549 xenotransplants was reduced as compared to the saline control group (n = 6) CD-1 nude mice (Fig. 3B). The CD13 expression in subcutaneous A549 xenotransplant is demonstrated by immunofluorescence; since the antibodies used for CD13 and CD31 staining are species-specific for human CD13 and CD31, vascular and perivascular staining were not assayed in the xenografts (Fig. 3C).
History
Usage metrics
Categories
Keywords
Results CD 13 expression270 NSCLC patientslung cancer histologiesCD 13-targeted tissue factor tTF-NGRNSCLC patientsCD 13 expressionMicroarray-based mRNA analysisCD 13 protein expression549 lung carcinoma xenotransplantsCD 13-targeted fusion protein tTF-NGRnon-small cell lung cancer Background Aminopeptidase NCD 13 mRNA expressionNSCLC study cohortKM plotter databaseCD 13III549 tumor growth
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC